

Selvarangan Ponnazhagan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/105247/publications.pdf>

Version: 2024-02-01

89
papers

4,055
citations

108046

37
h-index

145109

60
g-index

90
all docs

90
docs citations

90
times ranked

6146
citing authors

#	ARTICLE	IF	CITATIONS
1	Computational Simulation of Exosome Transport in Tumor Microenvironment. <i>Frontiers in Medicine</i> , 2021, 8, 643793.	1.2	7
2	Extracellular Vesicle Mediated Tumor-Stromal Crosstalk Within an Engineered Lung Cancer Model. <i>Frontiers in Oncology</i> , 2021, 11, 654922.	1.3	8
3	Hedgehog Signaling Regulates Metabolism and Polarization of Mammary Tumor-Associated Macrophages. <i>Cancer Research</i> , 2021, 81, 5425-5437.	0.4	50
4	Indoleamine 2, 3-Dioxygenase Promotes Aryl Hydrocarbon Receptor-Dependent Differentiation Of Regulatory B Cells in Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 747780.	2.2	8
5	A conserved aromatic moiety in the ectodomain is a key determinant for structural integrity and protein trafficking of TNFR superfamily. <i>FASEB Journal</i> , 2020, 34, 15687-15700.	0.2	0
6	RANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2585-2597.	1.9	3
7	Adeno-Associated Virus D-Sequence-Mediated Suppression of Expression of a Human Major Histocompatibility Class II Gene: Implications in the Development of Adeno-Associated Virus Vectors for Modulating Humoral Immune Response. <i>Human Gene Therapy</i> , 2020, 31, 565-574.	1.4	5
8	Mechanical strain induces phenotypic changes in breast cancer cells and promotes immunosuppression in the tumor microenvironment. <i>Laboratory Investigation</i> , 2020, 100, 1503-1516.	1.7	27
9	Runx2 Deficiency in Osteoblasts Promotes Myeloma Progression by Altering the Bone Microenvironment at New Bone Sites. <i>Cancer Research</i> , 2020, 80, 1036-1048.	0.4	18
10	Revisiting Immunotherapy: A Focus on Prostate Cancer. <i>Cancer Research</i> , 2020, 80, 1615-1623.	0.4	120
11	Recombinant AAV-CEA Tumor Vaccine in Combination with an Immune Adjuvant Breaks Tolerance and Provides Protective Immunity. <i>Molecular Therapy - Oncolytics</i> , 2019, 12, 41-48.	2.0	29
12	Structural determinants and genetic modifications enhance BMP2 stability and extracellular secretion. <i>FASEB BioAdvances</i> , 2019, 1, 180-190.	1.3	11
13	Characterization of immune cell subtypes in three commonly used mouse strains reveals gender and strain-specific variations. <i>Laboratory Investigation</i> , 2019, 99, 93-106.	1.7	67
14	Pathology, Chemoprevention, and Preclinical Models for Target Validation in Barrett Esophagus. <i>Cancer Research</i> , 2018, 78, 3747-3754.	0.4	2
15	Myeloid-Derived Suppressor Cells Impair B Cell Responses in Lung Cancer through IL-7 and STAT5. <i>Journal of Immunology</i> , 2018, 201, 278-295.	0.4	89
16	Endostatin inhibits androgen-independent prostate cancer growth by suppressing nuclear receptor-mediated oxidative stress. <i>FASEB Journal</i> , 2017, 31, 1608-1619.	0.2	11
17	Location of tumor affects local and distant immune cell type and number. <i>Immunity, Inflammation and Disease</i> , 2017, 5, 85-94.	1.3	14
18	Silencing of TGF- β 1 in tumor cells impacts MMP-9 in tumor microenvironment. <i>Scientific Reports</i> , 2017, 7, 8678.	1.6	41

#	ARTICLE	IF	CITATIONS
19	Mesenchymal stem cells expressing osteoprotegerin variants inhibit osteolysis in a murine model of multiple myeloma. <i>Blood Advances</i> , 2017, 1, 2375-2385.	2.5	8
20	Osteoclast proton pump regulator <i>Atp6v1c1</i> enhances breast cancer growth by activating the mTORC1 pathway and bone metastasis by increasing V-ATPase activity. <i>Oncotarget</i> , 2017, 8, 47675-47690.	0.8	33
21	Effects of Cellular Methylation on Transgene Expression and Site-Specific Integration of Adeno-Associated Virus. <i>Genes</i> , 2017, 8, 232.	1.0	12
22	Resveratrol induces mitochondria-mediated, caspase-independent apoptosis in murine prostate cancer cells. <i>Oncotarget</i> , 2017, 8, 20895-20908.	0.8	46
23	Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment. <i>Oncotarget</i> , 2016, 7, 75407-75424.	0.8	66
24	Prostate cancer-derived cathelicidin-related antimicrobial peptide facilitates macrophage differentiation and polarization of immature myeloid progenitors to protumorigenic macrophages. <i>Prostate</i> , 2016, 76, 624-636.	1.2	32
25	Immature myeloid cells are critical for enhancing bone fracture healing through angiogenic cascade. <i>Bone</i> , 2016, 93, 113-124.	1.4	16
26	SOCS3 Deficiency in Myeloid Cells Promotes Tumor Development: Involvement of STAT3 Activation and Myeloid-Derived Suppressor Cells. <i>Cancer Immunology Research</i> , 2015, 3, 727-740.	1.6	54
27	Endostatin: A novel inhibitor of androgen receptor function in prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 1392-1397.	3.3	37
28	Variants of Osteoprotegerin Lacking TRAIL Binding for Therapeutic Bone Remodeling in Osteolytic Malignancies. <i>Molecular Cancer Research</i> , 2015, 13, 819-827.	1.5	10
29	The dual targeting of immunosuppressive cells and oxidants promotes effector and memory T-cell functions against lung cancer. <i>Oncimmunology</i> , 2014, 3, e27401.	2.1	4
30	Anterior Gradient Protein-2 Is a Regulator of Cellular Adhesion in Prostate Cancer. <i>PLoS ONE</i> , 2014, 9, e89940.	1.1	17
31	Detection of Merkel cell polyomavirus in formalin-fixed, paraffin-embedded tissue of Merkel cell carcinoma and correlation with prognosis. <i>Romanian Journal of Morphology and Embryology</i> , 2014, 55, 1057-62.	0.4	4
32	Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer. <i>Cancer Research</i> , 2013, 73, 672-682.	0.4	153
33	Muscle-Directed Anti-A β Single-Chain Antibody Delivery via AAV1 Reduces Cerebral A β Load in an Alzheimer's Disease Mouse Model. <i>Journal of Molecular Neuroscience</i> , 2013, 49, 277-288.	1.1	20
34	Polyglutamate directed coupling of bioactive peptides for the delivery of osteoinductive signals on allograft bone. <i>Biomaterials</i> , 2013, 34, 1506-1513.	5.7	34
35	Role of plasmacytoid dendritic cells in breast cancer bone dissemination. <i>Oncimmunology</i> , 2013, 2, e22983.	2.1	17
36	Enhancement of Antitumor Immunity in Lung Cancer by Targeting Myeloid-Derived Suppressor Cell Pathways. <i>Cancer Research</i> , 2013, 73, 6609-6620.	0.4	75

#	ARTICLE	IF	CITATIONS
37	Myeloid-Derived Suppressor Cells as Osteoclast Progenitors: A Novel Target for Controlling Osteolytic Bone Metastasis. <i>Cancer Research</i> , 2013, 73, 4606-4610.	0.4	69
38	Myeloid-derived suppressor cells as a novel target for the control of osteolytic bone disease. <i>Oncolmunology</i> , 2013, 2, e24064.	2.1	12
39	Modulation of indoleamine 2,3-dioxygenase pathway by a combination therapy strategy targeting myeloid derived suppressor cell function in lung cancer. <i>FASEB Journal</i> , 2013, 27, 1105.25.	0.2	0
40	Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1441-1450.	2.0	33
41	Noggin Is Novel Inducer of Mesenchymal Stem Cell Adipogenesis. <i>Journal of Biological Chemistry</i> , 2012, 287, 12241-12249.	1.6	23
42	Depletion of Plasmacytoid Dendritic Cells Inhibits Tumor Growth and Prevents Bone Metastasis of Breast Cancer Cells. <i>Journal of Immunology</i> , 2012, 189, 4258-4265.	0.4	155
43	Mobilization of bone marrow mesenchymal stem cells in vivo augments bone healing in a mouse model of segmental bone defect. <i>Bone</i> , 2012, 50, 1012-1018.	1.4	96
44	Anti-Amyloid- β Single-Chain Antibody Brain Delivery Via AAV Reduces Amyloid Load But May Increase Cerebral Hemorrhages in an Alzheimer's Disease Mouse Model. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 23-38.	1.2	33
45	LL-37 as a therapeutic target for late stage prostate cancer. <i>Prostate</i> , 2011, 71, 659-670.	1.2	43
46	Conditionally Replicating Adenovirus Expressing TIMP2 for Ovarian Cancer Therapy. <i>Clinical Cancer Research</i> , 2011, 17, 538-549.	3.2	33
47	Conditionally Replicating Adenovirus Expressing TIMP2 Increases Survival in a Mouse Model of Disseminated Ovarian Cancer. <i>PLoS ONE</i> , 2011, 6, e25131.	1.1	9
48	Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in diseases of the skeleton. <i>Journal of Cellular Biochemistry</i> , 2010, 111, 249-257.	1.2	110
49	Mesenchymal Stem Cells Expressing Osteogenic and Angiogenic Factors Synergistically Enhance Bone Formation in a Mouse Model of Segmental Bone Defect. <i>Molecular Therapy</i> , 2010, 18, 1026-1034.	3.7	143
50	Bacteriophage hyaluronidase effectively inhibits growth, migration and invasion by disrupting hyaluronan-mediated Erk1/2 activation and RhoA expression in human breast carcinoma cells. <i>Cancer Letters</i> , 2010, 298, 238-249.	3.2	13
51	Therapeutic Potential of Adult Bone Marrow-Derived Mesenchymal Stem Cells in Prostate Cancer Bone Metastasis. <i>Clinical Cancer Research</i> , 2009, 15, 7175-7185.	3.2	50
52	Tumorstatic effects of endostatin in prostate cancer is dependent on androgen receptor status. <i>Prostate</i> , 2009, 69, 1055-1066.	1.2	10
53	Free fatty acids enhance breast cancer cell migration through plasminogen activator inhibitor-1 and SMAD4. <i>Laboratory Investigation</i> , 2009, 89, 1221-1228.	1.7	46
54	Therapeutic Potential of Mesenchymal Stem Cells Producing Interferon- β in a Mouse Melanoma Lung Metastasis Model. <i>Stem Cells</i> , 2008, 26, 2332-2338.	1.4	181

#	ARTICLE	IF	CITATIONS
55	Telomere Maintenance in Laser Capture Microdissectionâ€“Purified Barrett's Adenocarcinoma Cells and Effect of Telomerase Inhibition <i>In vivo</i>. <i>Clinical Cancer Research</i> , 2008, 14, 4971-4980.	3.2	39
56	Systemic Osteoprotegerin Gene Therapy Restores Tumor-induced Bone Loss in a Therapeutic Model of Breast Cancer Bone Metastasis. <i>Molecular Therapy</i> , 2008, 16, 871-878.	3.7	32
57	Silencing of Transforming Growth Factor- β 1 <i>In situ</i> by RNA Interference for Breast Cancer: Implications for Proliferation and Migration <i>In vitro</i> and Metastasis <i>In vivo</i>. <i>Clinical Cancer Research</i> , 2008, 14, 4961-4970.	3.2	48
58	Genetic Modification of Adeno-Associated Viral Vector Type 2 Capsid Enhances Gene Transfer Efficiency in Polarized Human Airway Epithelial Cells. <i>Human Gene Therapy</i> , 2008, 19, 1407-1414.	1.4	27
59	Clinical significance of a novel single nucleotide polymorphism in the 5' untranslated region of the Rabphilin-3A-Like gene in colorectal adenocarcinoma. <i>Frontiers in Bioscience - Landmark</i> , 2008, 13, 1050.	3.0	8
60	Notch1 Augments Intracellular Trafficking of Adeno-Associated Virus Type 2. <i>Journal of Virology</i> , 2007, 81, 2069-2073.	1.5	12
61	Bone homing of mesenchymal stem cells by ectopic α 4 integrin expression. <i>FASEB Journal</i> , 2007, 21, 3917-3927.	0.2	153
62	Effects of Sustained Antiangiogenic Therapy in Multistage Prostate Cancer in TRAMP Model. <i>Cancer Research</i> , 2007, 67, 5789-5797.	0.4	44
63	Anti-A β single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease. <i>Neurobiology of Disease</i> , 2006, 23, 502-511.	2.1	84
64	Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor. <i>Cancer Gene Therapy</i> , 2005, 12, 26-34.	2.2	31
65	Determination of osteoprogenitor-specific promoter activity in mouse mesenchymal stem cells by recombinant adeno-associated virus transduction. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 2005, 1731, 95-103.	2.4	25
66	Protein Transduction of Dendritic Cells for NY-ESO-1-Based Immunotherapy of Myeloma. <i>Cancer Research</i> , 2005, 65, 10041-10049.	0.4	61
67	Genomic Stability of Self-Complementary Adeno-Associated Virus 2 During Early Stages of Transduction in Mouse Muscle <i>In Vivo</i> . <i>Human Gene Therapy</i> , 2005, 16, 1047-1057.	1.4	26
68	Recombinant adeno-associated virus 2-mediated antiangiogenic prevention in a mouse model of intraperitoneal ovarian cancer. <i>Clinical Cancer Research</i> , 2005, 11, 1342-7.	3.2	18
69	Augmentation of Antitumor Activity of a Recombinant Adeno-Associated Virus Carcinoembryonic Antigen Vaccine with Plasmid Adjuvant. <i>Human Gene Therapy</i> , 2004, 15, 856-864.	1.4	16
70	Adeno-Associated Virus 2-Mediated Antiangiogenic Cancer Gene Therapy. <i>Cancer Research</i> , 2004, 64, 1781-1787.	0.4	74
71	Parvovirus vectors for cancer gene therapy. <i>Expert Opinion on Biological Therapy</i> , 2004, 4, 53-64.	1.4	10
72	Osteogenic Differentiation of Recombinant Adeno-Associated Virus 2-Transduced Murine Mesenchymal Stem Cells and Development of an Immunocompetent Mouse Model for <i>Ex Vivo</i> Osteoporosis Gene Therapy. <i>Human Gene Therapy</i> , 2004, 15, 1197-1206.	1.4	59

#	ARTICLE	IF	CITATIONS
73	Gene Therapy for Osteoinduction. <i>Current Gene Therapy</i> , 2004, 4, 287-296.	0.9	3
74	Conjugate-Based Targeting of Adeno-Associated Virus Vectors. , 2003, , 201-219.		0
75	Conjugate-Based Targeting of Recombinant Adeno-Associated Virus Type 2 Vectors by Using Avidin-Linked Ligands. <i>Journal of Virology</i> , 2002, 76, 12900-12907.	1.5	116
76	Adenoassociated Virus Vectors for Genetic Immunization. <i>Immunologic Research</i> , 2002, 26, 247-254.	1.3	7
77	Adeno-Associated Virus Type 2-Mediated Transduction of Human Monocyte-Derived Dendritic Cells: Implications for Ex Vivo Immunotherapy. <i>Journal of Virology</i> , 2001, 75, 9493-9501.	1.5	76
78	Adeno-Associated Virus 2-Mediated Transduction and Erythroid Lineage-Restricted Expression from Parvovirus B19p6 Promoter in Primary Human Hematopoietic Progenitor Cells. <i>Journal of Hematotherapy and Stem Cell Research</i> , 1999, 8, 585-592.	1.8	17
79	Adeno-Associated Virus Type 2-Mediated Gene Transfer: Role of Epidermal Growth Factor Receptor Protein Tyrosine Kinase in Transgene Expression. <i>Journal of Virology</i> , 1998, 72, 9835-9843.	1.5	92
80	Adeno-Associated Virus Type 2-Mediated Gene Transfer: Correlation of Tyrosine Phosphorylation of the Cellular Single-Stranded D Sequence-Binding Protein with Transgene Expression in Human Cells In Vitro and Murine Tissues In Vivo. <i>Journal of Virology</i> , 1998, 72, 1593-1599.	1.5	118
81	Recombinant Human Parvovirus B19 Vectors: Erythroid Cell-Specific Delivery and Expression of Transduced Genes. <i>Journal of Virology</i> , 1998, 72, 5224-5230.	1.5	46
82	Characterization of Wild-Type Adeno-Associated Virus Type 2-Like Particles Generated during Recombinant Viral Vector Production and Strategies for Their Elimination. <i>Journal of Virology</i> , 1998, 72, 5472-5480.	1.5	61
83	Evaluation of recombinant adeno-associated virus as a gene transfer vector for the retina. <i>Current Eye Research</i> , 1997, 16, 949-956.	0.7	71
84	Lack of Site-Specific Integration of the Recombinant Adeno-Associated Virus 2 Genomes in Human Cells. <i>Human Gene Therapy</i> , 1997, 8, 275-284.	1.4	142
85	Adeno-associated virus 2-mediated gene transfer in vivo: organ-tropism and expression of transduced sequences in mice. <i>Gene</i> , 1997, 190, 203-210.	1.0	128
86	Mousesilver.mutation is caused by a single base insertion in the putative cytoplasmic domain of Pmel 17. <i>Nucleic Acids Research</i> , 1995, 23, 154-158.	6.5	77
87	Rescue and Replication Signals of the Adeno-associated Virus 2 Genome. <i>Journal of Molecular Biology</i> , 1995, 250, 573-580.	2.0	67
88	Cord Blood Transplantation and the Potential for Gene Therapy.. <i>Annals of the New York Academy of Sciences</i> , 1995, 770, 105-115.	1.8	15
89	Structural Organization of the Human Tyrosinase Gene and Sequence Analysis and Characterization of its Promoter Region. <i>Journal of Investigative Dermatology</i> , 1994, 102, 744-748.	0.3	45